Cellebrite DI (NASDAQ:CLBT) Posts Earnings Results, Misses Estimates By $0.05 EPS

Cellebrite DI (NASDAQ:CLBT) released its quarterly earnings data on Wednesday. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05), Zacks reports. The company had revenue of $126.03 million during the quarter, compared to the consensus estimate of $122.98 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The company’s revenue for the quarter was up 17.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.14 EPS. Cellebrite DI updated its FY 2025 guidance to EPS and its Q4 2025 guidance to EPS.

Cellebrite DI Price Performance

CLBT opened at $15.97 on Thursday. The firm has a market capitalization of $3.82 billion, a P/E ratio of -21.01, a PEG ratio of 3.16 and a beta of 1.28. The company’s 50-day moving average is $17.72 and its 200 day moving average is $16.69. Cellebrite DI has a fifty-two week low of $13.10 and a fifty-two week high of $26.30.

Hedge Funds Weigh In On Cellebrite DI

Large investors have recently made changes to their positions in the stock. Invesco Ltd. boosted its position in shares of Cellebrite DI by 6.4% during the 2nd quarter. Invesco Ltd. now owns 3,505,552 shares of the company’s stock valued at $56,089,000 after acquiring an additional 209,473 shares during the last quarter. Qube Research & Technologies Ltd increased its holdings in shares of Cellebrite DI by 93.7% in the second quarter. Qube Research & Technologies Ltd now owns 1,500,505 shares of the company’s stock worth $24,008,000 after buying an additional 725,679 shares during the period. Raymond James Financial Inc. increased its stake in shares of Cellebrite DI by 54.9% in the second quarter. Raymond James Financial Inc. now owns 1,415,346 shares of the company’s stock worth $22,646,000 after buying an additional 501,625 shares during the period. Man Group plc grew its stake in shares of Cellebrite DI by 44.1% in the second quarter. Man Group plc now owns 731,589 shares of the company’s stock worth $11,705,000 after purchasing an additional 223,941 shares during the last quarter. Finally, Cubist Systematic Strategies LLC increased its stake in shares of Cellebrite DI by 75.2% during the second quarter. Cubist Systematic Strategies LLC now owns 557,240 shares of the company’s stock valued at $8,916,000 after buying an additional 239,257 shares during the period. 45.88% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently issued reports on CLBT. Wall Street Zen downgraded Cellebrite DI from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. JPMorgan Chase & Co. upped their price objective on Cellebrite DI from $20.00 to $23.00 and gave the company an “overweight” rating in a report on Wednesday, September 24th. Lake Street Capital reduced their price target on Cellebrite DI from $24.00 to $22.00 and set a “buy” rating on the stock in a research report on Friday, August 15th. Needham & Company LLC dropped their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, August 14th. Finally, Weiss Ratings raised Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, November 7th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $21.00.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.